Ann: Appendix 4C - quarterly, page-110

On the 31st of March this Year lee Rodney was talking about expansion into Hong Kong as part of Admedus’ global product launch strategy

Reflecting on the number of procedures, he was quoted as saying

"Over 1,200 patients have been treated using CardioCel as part of their cardiovascular repair surgery."


The company says that it has already received initial orders for CardioCel, a bio-scaffold used to repair congenital heart deformities and complex heart defects including repairing heart valves. “The initial sales in Hong Kong are important as these countries represent significant cardiovascular markets in the Asian region,” said Admedus chief executive officer Lee Rodne. “Expansion in this region is part of our global strategy for CardioCel.”

Remember that this was said March 31 this year, which brings me to my point that I believe that Hong Kong was probably the catalyst and responsible for the majority increase in procedures last Quarter.